Filtered By:
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 68 results found since Jan 2013.
Cost‐Effectiveness of High‐Dose Edoxaban Compared with Adjusted‐Dose Warfarin for Stroke Prevention in Non–Valvular Atrial Fibrillation Patients
ConclusionsHigh‐dose edoxaban appears to be an economically dominant strategy when compared with adjusted‐dose warfarin for the prevention of stroke in NVAF patients with a Clcr of 15–95 ml/minute and an appreciable risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 26, 2016 Category: Drugs & Pharmacology Authors: Elaine Nguyen, Florence Egri, Elizabeth S. Mearns, Charles M. White, Craig I. Coleman Tags: Original Research Article Source Type: research
Cost‐Effectiveness of High‐Dose Edoxaban Compared to Adjusted‐Dose Warfarin for Stroke Prevention in Non‐Valvular Atrial Fibrillation Patients
ConclusionsHigh‐dose edoxaban appears to be an economically dominant strategy when compared to adjusted‐dose warfarin for the prevention of stroke in NVAF patients with a CrCl of 15‐95 mL/minute and an appreciable risk of stroke.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 29, 2016 Category: Drugs & Pharmacology Authors: Elaine Nguyen, Florence Egri, Elizabeth S. Mearns, Charles M. White, Craig I. Coleman Tags: Original Research Article Source Type: research
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin
We describe the first case report, to our knowledge, documenting a drug interaction between phenytoin and dabigatran by using laboratory measurements of dabigatran serum concentrations. A 45‐year‐old African‐American man was admitted to the inpatient cardiology service following defibrillations from his implantable cardioverter defibrillator. The patient was evaluated and received appropriate antitachycardia pacing for atrial tachyarrhythmias for an episode of ventricular tachycardia (VT), and antiarrhythmic therapy with sotalol was initiated to reduce both his AF and VT burden. On review of the patient's medications...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 5, 2016 Category: Drugs & Pharmacology Authors: Barbara S. Wiggins, Amanda Northup, Dominic Johnson, Jeffrey Senfield Tags: Case Report Source Type: research
The Role of Statin Therapy in Hemorrhagic Stroke
The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) are the most widely utilized class of cholesterol‐lowering agents, carrying multiple indications for both primary and secondary cardiovascular risk reduction. Concern was raised by previously published post hoc analyses and observational studies that noted an increased risk of hemorrhagic stroke in patients receiving a statin. Subsequent studies have demonstrated conflicting results regarding the role of statin therapy on hemorrhagic stroke risk and patient outcomes. New evidence suggests that statins taken prior to or continued during admissi...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 19, 2015 Category: Drugs & Pharmacology Authors: Andrea Sikora Newsome, Bryan C. Casciere, J. Dedrick Jordan, Denise H. Rhoney, Kelly A. Sullivan, Kathryn A. Morbitzer, Joseph D. Moore, Emily A. Durr Tags: Review of Therapeutics Source Type: research
Predictors of Gastrointestinal Bleeding Among Patients with Atrial Fibrillation After Initiating Dabigatran Therapy
ConclusionThe risk of GI bleeding in patients receiving dabigatran is highly associated with increased age and cardiovascular, renal, and other comorbidities, even after adjusting for other factors. Fewer than 50% of patients restarted an anticoagulant after experiencing a GI bleed. Clinicians should continue to monitor for these risk factors or consider whether alternative therapies may be appropriate.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2015 Category: Drugs & Pharmacology Authors: Julie C. Lauffenburger, Denise H. Rhoney, Joel F. Farley, Anil K. Gehi, Gang Fang Tags: Original Research Article Source Type: research
Recent Advances in the Development of Specific Antidotes for Target‐Specific Oral Anticoagulants
Warfarin, a vitamin K antagonist, has been the only orally available anticoagulant for > 60 years. During the past decade, the U.S. Food and Drug Administration has approved several target‐specific oral anticoagulants (TSOACs) for the prophylaxis and treatment of arterial and venous thromboembolism and stroke prevention in patients with nonvalvular atrial fibrillation. These new agents have several advantages over warfarin including more predictable pharmacokinetics and pharmacodynamics, fewer food and drug interactions, and lack of need for routine coagulation monitoring. However, unlike warfarin, currently no ant...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 3, 2015 Category: Drugs & Pharmacology Authors: Yoonsun Mo, Felix K. Yam Tags: Review of Therapeutics Source Type: research
Successful Use of Tetrabenazine in a Patient with Intractable Hiccups After Stroke
We describe the case of a 60‐year‐old man with a recent diagnosis of right insular ischemic stroke who presented with frequent, intense, and disabling hiccups for more than 1 month. As diagnosis of poststroke hiccups was assumed, the patient was treated over the next 6 months with adequate doses of various antipsychotic drugs commonly used for the treatment of hiccups; however, all were discontinued because of adverse effects. Indeed, dyskinesia after chlorpromazine (up to 75 mg/day for 4 wks), as well as somnolence and dyskinesia after haloperidol (up to 6 mg/day for 6 wks), somnolence after gabapentin (up to 18...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 4, 2014 Category: Drugs & Pharmacology Authors: Antonino Naro, Placido Bramanti, Rocco Salvatore Calabrò Tags: Case Report Source Type: research
Thrombosis in Continuous‐Flow Left Ventricular Assist Devices: Pathophysiology, Prevention, and Pharmacologic Management
Continuous‐flow left ventricular assist devices reduce short‐term mortality and improve quality of life in patients with end‐stage heart failure. Unfortunately, device‐related complications remain common, with many patients experiencing adverse events within the first year. New literature suggests that rates of device‐related thrombosis may be increasing since 2011, which is particularly troublesome given that this pathology can result in a disabling stroke, organ damage, and death. In 2013, a group of practitioners in the field of mechanical circulatory support published a treatment algorithm based on their expe...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 20, 2014 Category: Drugs & Pharmacology Authors: Douglas L. Jennings, Phillip A. Weeks Tags: Review of Therapeutics Source Type: research
